JonesResearch initiated coverage of Capricor Therapeutics (CAPR) with a Buy rating and $40 price target Capricor’s lead asset is deramiocel, a mutation-agnostic cell therapy for Duchenne muscular dystrophy cardiomyopathy, the analyst tells investors in a research note. The firm likes deramiocel, saying Cardiomyopathy is now the leading cause of death in DMD and there are no approved therapies for this indication. Cardiologist feedback indicates high level of excitement for deramiocel, contends the firm.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAPR:
- Capricor Therapeutics price target raised to $30 from $25 at Cantor Fitzgerald
- Capricor Therapeutics Advances with Strategic Expansions
- Capricor Therapeutics reports Q3 EPS (38c), consensus (36c)
- Capricor Therapeutics options imply 8.1% move in share price post-earnings
- CAPR Earnings this Week: How Will it Perform?